Immunicum Competitors and Similar CompaniesClear all
Camurus's competitors and similar companies include JCR Pharmaceuticals and GBT (Global Blood Therapeutics).
 Camurus Camurus is a research-based pharmaceutical company that develops medicines for severe and chronic conditions. |  JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. | |
Founding Date | Founding Date 1991 | Founding Date 1975 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Lund, SE HQ Sydney, AU Mannheim, DE Duxford, GB | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB |
Employees | Employees 265 | Employees 934 | Employees 352106% increase |
Valuation ($) | Valuation ($) 3.4 b | Valuation ($) 533.9 m | Valuation ($) 4.4 b |
Financial | |||
Revenue (est.) | Revenue (est.) kr2.3b (FY, 2025) | Revenue (est.) ¥40.3b (FY, 2026) | Revenue (est.) $194.7m (FY, 2021) |
Cost of goods | Cost of goods kr138.7m (FY, 2025) | Cost of goods ¥7.6b (FY, 2026) | Cost of goods $3.3m (FY, 2021) |
Gross profit | Gross profit kr2.1b (FY, 2025) | Gross profit ¥32.7b (FY, 2026) | Gross profit N/A |
Net income | Net income kr735.6m (FY, 2025) | Net income ¥2.2b (FY, 2026) | Net income ($303.1m) (FY, 2021) |
For sources of this data, please see the company profile
View Company Profiles
JCR Pharmaceuticals
HQ
Ashiya, JP
Employees
934
JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View company